ArticleMedical oncology (Northwood, London, England)2014
Elevated expression of CRYAB predicts unfavorable prognosis in non-small cell lung cancer.
Article in Medical oncology (Northwood, London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Systems-level effects of ectopic galectin-7 reconstitution in cervical cancer and its microenvironment.BMC cancer · 2016Pooled it
- Expression characteristics and biological significance of exosome-related genes in lung cancer.Discover oncology · 2025Article
- Review
- Bioinformatics analysis of key biomarkers for bladder cancer.Biomedical reports · 2023Article
- Role of methylation-related genesAnnals of translational medicine · 2022Article
- The role ofFrontiers in surgery · 2022Article
- A novel signature constructed by ferroptosis-associated genes (FAGs) for the prediction of prognosis in bladder urothelial carcinoma (BLCA) and associated with immune infiltration.Cancer cell international · 2021Article
- Two high-yield complementary methods to sort cell populations by their 2D or 3D migration speed.Molecular biology of the cell · 2020Article
- Small Heat Shock Proteins in Cancers: Functions and Therapeutic Potential for Cancer Therapy.International journal of molecular sciences · 2020Review
- BTLA Expression in Stage I-III Non-Small-Cell Lung Cancer and Its Correlation with PD-1/PD-L1 and Clinical Outcomes.OncoTargets and therapy · 2020Article
- Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities.Cancers · 2019Review
- High α B-crystallin and p53 co-expression is associated with poor prognosis in ovarian cancer.Bioscience reports · 2019Article
- Progression of the role of CRYAB in signaling pathways and cancers.OncoTargets and therapy · 2019Review
- Integrative analysis of transcriptomics and clinical data uncovers the tumor-suppressive activity of MITF in prostate cancer.Cell death & disease · 2018Article
- Alpha B-crystallin C-802G polymorphism and colorectal cancer susceptibility and clinical outcome in Chinese population.Scientific reports · 2018Article
- High expression of NDRG3 associates with unfavorable overall survival in non-small cell lung cancer.Cancer biomarkers : section A of Disease markers · 2018Article
- SESN2 correlates with advantageous prognosis in hepatocellular carcinoma.Diagnostic pathology · 2017Article
- αB-crystallin: Portrait of a malignant chaperone as a cancer therapeutic target.Pharmacology & therapeutics · 2016Review
- Therapeutic potential of α-crystallin.Biochimica et biophysica acta · 2016Review
- Uncovering Driver DNA Methylation Events in Nonsmoking Early Stage Lung Adenocarcinoma.BioMed research international · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha B-crystallin (CRYAB) is one of the principal members of the small heat-shock protein family, and several studies described the CRYAB expression in human cancers. However, the association between CRYAB expression and the clinical features of non-small cell lung cancer (NSCLC) is rarely elucidated. In this present study, one-step quantitative reverse transcription-polymerase chain reaction with 12 fresh-frozen NSCLC samples and Western blotting as well as immunohistochemistry (IHC) analyses in 101 NSCLC cases were conducted to investigate the relationship between CRYAB expression and the clinicopathological attributes of NSCLC. The results showed that CRYAB mRNA and protein expression levels were significantly higher in NSCLC than in matched non-cancerous tissues (p < 0.05). The IHC data indicated that the CRYAB protein expression in NSCLC was significantly correlated with TNM stage (p = 0.043), and overall survival (p = 0.029). Kaplan-Meier method and Cox multifactor analysis suggested that higher CRYAB protein level (p = 0.032) and TNM stage (p = 0.048) were statistically associated with the poor survival of patients with NSCLC. The data suggested that CRYAB may be identified as a novel prognostic marker and targeting CRYAB may provide a promising strategy for NSCLC treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.